Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR

Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com